HeartSciences Records Inventory Write-Down Due to MyoVista wavECG Commercialization Uncertainty

Filing content

HeartSciences recorded a $0.3 million inventory write-down for its MyoVista wavECG device as it cannot currently establish a probable timeline for commercialization.